BreatheSuite
A Medical Device
in your pocket
Eric Larson,
PhD Candidate,
Electrical Engineering.
Commercialized past
patent to Belkin.
Co-lead on
BreatheSuite’s patent...
Shwetak Patel
UW Professor in CSE &
EE,
MacArthur Genius Grant
Recipient
Jim Stout, MD
UW Medicine, Spirometry
360 Creator...
Asthma
COPD
Cystic Fibrosis
Chronic Respiratory Disease
World Health Organization
World Asthma Foundation
1 out of every 7 people
have a respiratory
disease
Diagnosis: Spirometer
measures volume and
flow of air from the lungs
90% of hospitals in developing
nations do not have spirometers
Solution: BreatheSuite
From Any Phone
Everyone has access
BreatheSuite’s Impact
Reduce hospitalizations
Fewer deaths
Head To Head Evaluation
Head To Head Evaluation
Test results identical
International Conference on Ubiquitous Computing, 2012
Head To Head Evaluation
Test results identical
Doctor diagnosis identical
International Conference on Ubiquitous Computing...
Current Status
Current Status
Current Status
Current Status
Traction: In The News
Traction: Key Customers
Traction: Key Customers
Global Health Non-
Profits
Global Health Non-Profits
Handles: Developing World Healthcare
Needs: mHealth solutions
Global Health Market
1 Billion People
6 Billion Phones
World Health Organization
Global Health Non-Profits
Traction: Key Customers
Global Health Non-
Profits
Traction: Key Customers
PharmaceuticalsGlobal Health Non-
Profits
Pharmaceuticals: Clinical
Trials
Market: 6000+ respiratory trials
Cost: $1 B per drug
Time: 15 years per drug
Go To Market
Pharmaceuticals
DevelopingWorld
Secondary Markets
Business Model
PharmaceuticalsGlobal Health Non-
Profits
Setup fee
Per Trial, Per Patient fee
Shared Distribution Channels...
Competition
Full Diagnosis
Limited Diagnosis
SoftwareHardware
Spirometers
Peak Flow Meters FEV1 Meters
BreatheSuite
Financial Summary
$-
$10
$20
$30
$40
$50
$60
2013
2014
2015
Millions
2013 2014 2015
Revenue $7 $21 $41
Net Income $3 $10 $...
Social Return On Investment
Social Return On Investment
Fewer deaths from COPD and asthma
a 10% reduction = 325,000 lives
return of 65M – 1.3B dollars...
Social Return On Investment
Fewer hospitalizations
a 10% reduction > 1M hospital stays
return of 600M – 4B dollars per yea...
Social Return On Investment
Every dollar spent =
conservative: 2.6 dollars of impact
more realistic: 8.6 dollars of impact
Offer
Grant Funding:
$800,000
with $100,000
committed
Equity Funding:
$3M-$5M
Grant funding:
commercialization &
regulator...
Thank you
Thanks to:
Deb Wolf & the GSEC staff,
Greg Free
GSEC judges and volunteers
BreatheSuite’s board of advisors
The ...
BreatheSuite
A Medical Device
in your pocket
Appendix: How It Works
Audio
Vocal Tract
Model
Flow rate
Appendix: Side By Side
Comparison
Raw Audio: 5.2%
Call In Service:6.4%
ATS Range: 5-7%
Appendix: Leading Causes of Death
World Health Organization
Appendix: Disability Adjusted Life Years
Global Burden of Disease, 2007
Global Health Non-Profits
Appendix: Financials: Pharma
Pharma Revenue Projections
Pharma Cost Projections
Appendix: Financials: Dev World
Dev World Cost Assumptions
DevWorld Revenues have not been factored into our overall initi...
Appendix: Income Statement & FCF
Appendix: Social Impact Summary
Inputs Outputs Outcomes Impacts
$8 M-$39 M
$220M-$2.4 B
$2 B-119 B
$9 B-$365 B
Drugs broug...
Appendix: Social Impact Summary
Inputs Outputs Outcomes Impacts
$8 M-$39 M
$220M-$2.4 B
$20 B-119 B
$20 B-$365 B
Drugs bro...
BreatheSuite
Upcoming SlideShare
Loading in …5
×

BreatheSuite

271 views
199 views

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
271
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

BreatheSuite

  1. 1. BreatheSuite A Medical Device in your pocket
  2. 2. Eric Larson, PhD Candidate, Electrical Engineering. Commercialized past patent to Belkin. Co-lead on BreatheSuite’s patents. Matt Jasper, MBA Candidate Founded 2 IP licensing businesses. Handles customer development. Mayank Goel, PhD Candidate, Computer Science. Founded home automation business. Co-lead on BreatheSuite’s patents. BreatheSuite Team
  3. 3. Shwetak Patel UW Professor in CSE & EE, MacArthur Genius Grant Recipient Jim Stout, MD UW Medicine, Spirometry 360 Creator, Primary Care Physician Margaret Rosenfeld, MD Seattle Children’s Hospital, Clinical Pulmonologist Rachael Tanner & Kathie Jordan, Coulter Foundation David Hammond, Regulatory Consultant Greg Free, GSEC Mentor Board of Advisors
  4. 4. Asthma COPD Cystic Fibrosis Chronic Respiratory Disease
  5. 5. World Health Organization World Asthma Foundation 1 out of every 7 people have a respiratory disease
  6. 6. Diagnosis: Spirometer measures volume and flow of air from the lungs
  7. 7. 90% of hospitals in developing nations do not have spirometers
  8. 8. Solution: BreatheSuite
  9. 9. From Any Phone
  10. 10. Everyone has access
  11. 11. BreatheSuite’s Impact Reduce hospitalizations Fewer deaths
  12. 12. Head To Head Evaluation
  13. 13. Head To Head Evaluation Test results identical International Conference on Ubiquitous Computing, 2012
  14. 14. Head To Head Evaluation Test results identical Doctor diagnosis identical International Conference on Ubiquitous Computing, 2012
  15. 15. Current Status
  16. 16. Current Status
  17. 17. Current Status
  18. 18. Current Status
  19. 19. Traction: In The News
  20. 20. Traction: Key Customers
  21. 21. Traction: Key Customers Global Health Non- Profits
  22. 22. Global Health Non-Profits Handles: Developing World Healthcare Needs: mHealth solutions
  23. 23. Global Health Market 1 Billion People 6 Billion Phones World Health Organization
  24. 24. Global Health Non-Profits
  25. 25. Traction: Key Customers Global Health Non- Profits
  26. 26. Traction: Key Customers PharmaceuticalsGlobal Health Non- Profits
  27. 27. Pharmaceuticals: Clinical Trials Market: 6000+ respiratory trials Cost: $1 B per drug Time: 15 years per drug
  28. 28. Go To Market Pharmaceuticals DevelopingWorld Secondary Markets
  29. 29. Business Model PharmaceuticalsGlobal Health Non- Profits Setup fee Per Trial, Per Patient fee Shared Distribution Channels Paid Use Model via Buyers
  30. 30. Competition Full Diagnosis Limited Diagnosis SoftwareHardware Spirometers Peak Flow Meters FEV1 Meters BreatheSuite
  31. 31. Financial Summary $- $10 $20 $30 $40 $50 $60 2013 2014 2015 Millions 2013 2014 2015 Revenue $7 $21 $41 Net Income $3 $10 $18 Break Even in Year 1 M M M M M M
  32. 32. Social Return On Investment
  33. 33. Social Return On Investment Fewer deaths from COPD and asthma a 10% reduction = 325,000 lives return of 65M – 1.3B dollars per year World Health Organization Burden of Obstructive Lung Disease World Asthma Foundation
  34. 34. Social Return On Investment Fewer hospitalizations a 10% reduction > 1M hospital stays return of 600M – 4B dollars per year World Health Organization Burden of Obstructive Lung Disease World Asthma Foundation
  35. 35. Social Return On Investment Every dollar spent = conservative: 2.6 dollars of impact more realistic: 8.6 dollars of impact
  36. 36. Offer Grant Funding: $800,000 with $100,000 committed Equity Funding: $3M-$5M Grant funding: commercialization & regulatory approval Equity Funding: Technology scaling & sales
  37. 37. Thank you Thanks to: Deb Wolf & the GSEC staff, Greg Free GSEC judges and volunteers BreatheSuite’s board of advisors The University of Washington BreatheSuite A Medical Device in your pocketwww.breathesuite.com info@breathesuite.com @breathesuite
  38. 38. BreatheSuite A Medical Device in your pocket
  39. 39. Appendix: How It Works Audio Vocal Tract Model Flow rate
  40. 40. Appendix: Side By Side Comparison Raw Audio: 5.2% Call In Service:6.4% ATS Range: 5-7%
  41. 41. Appendix: Leading Causes of Death World Health Organization
  42. 42. Appendix: Disability Adjusted Life Years Global Burden of Disease, 2007
  43. 43. Global Health Non-Profits
  44. 44. Appendix: Financials: Pharma Pharma Revenue Projections Pharma Cost Projections
  45. 45. Appendix: Financials: Dev World Dev World Cost Assumptions DevWorld Revenues have not been factored into our overall initial BreatheSuite revenue projections, as the Pharma Revenue is more than enough to cover both pharma and dev world costs. However, we are building out a paid use model with developing world global health partners that includes revenue that will both cover costs, provide healthy margins, and be affordable to those who need our technology the most.
  46. 46. Appendix: Income Statement & FCF
  47. 47. Appendix: Social Impact Summary Inputs Outputs Outcomes Impacts $8 M-$39 M $220M-$2.4 B $2 B-119 B $9 B-$365 B Drugs brought to market quicker Increased rates of smoking cessation Less hospitalization, self management of disease, better health More trials have integrated spirometry results Spirometry provides teaching moment for smokers Increased number of people performing spirometry Increased number of people performing spirometry Cost of application, cost of training in new trials Doctors, Education & Ad Campaigns, Application Services Time, Access to phone, Remote Care Workers, Doctors Time, Access to phone, Remote Care Workers, Doctors Pharmaceuticals Developing Respiratory Drugs Global Health Non-Profits Undiagnosed COPD patients Undiagnosed Asthma Patients Stakeholders Less hospitalization, self management of disease, better health Total Impact $40 B – $524 B $8 M-$39 M $220M-$2.4 B $20 B-119 B $20 B-$365 B
  48. 48. Appendix: Social Impact Summary Inputs Outputs Outcomes Impacts $8 M-$39 M $220M-$2.4 B $20 B-119 B $20 B-$365 B Drugs brought to market quicker Increased rates of smoking cessation Less hospitalization, self management of disease, better health More trials have integrated spirometry results Spirometry provides teaching moment for smokers Increased number of people performing spirometry Increased number of people performing spirometry Cost of application, cost of training in new trials Doctors, Education & Ad Campaigns, Application Services Time, Access to phone, Remote Care Workers, Doctors Time, Access to phone, Remote Care Workers, Doctors Pharmaceuticals Developing Respiratory Drugs Global Health Non-Profits Undiagnosed COPD patients Undiagnosed Asthma Patients Stakeholders Less hospitalization, self management of disease, better health Totals $40 B – $524 B $4.1B/yr $10.6B- $35B/yr

×